| Name | Bosentan |
| Classes |
Cardiovascular Agent Antihypertensive |
| Diseases |
Pulmonary Disease Pulmonary Hypertension |
Bangla
EnglishBosentan
Bosentan is classified as an endothelin receptor antagonist. It works by blocking the action of endothelin, a substance in the body that causes blood vessels to narrow and increase blood pressure. Bosentan helps to relax blood vessels and reduce blood pressure, improving blood flow in patients with pulmonary arterial hypertension (PAH).
Bosentan is used for the treatment of pulmonary arterial hypertension (PAH) in patients with WHO Functional Class II-IV symptoms to improve exercise ability and delay clinical worsening. It is also used to reduce the number of new digital ulcers in patients with systemic sclerosis and ongoing digital ulcer disease.
- Patients older than 12 years of age: initiate at 62.5 mg orally twice daily; for patients weighing greater than 40 kg, increase to 125 mg orally twice daily after 4 weeks
- Patients 12 years of age and younger: dosage is is based on weight.
- Reduce the dose and closely monitor patients developing aminotransferase elevations more than 3x Upper Limit of Normal (ULN)
The following adverse reactions have been reported in patients receiving Bosentan:
- respiratory tract infection
- anemia
- pyrexia
- nasal congestion
- Fluid retention: May require intervention.
- Pulmonary veno-occlusive disease (PVOD): If signs of pulmonary edema occur, consider the diagnosis of associated PVOD and consider discontinuing Bosentan.
- Decreased sperm counts have been reported
- Decreases in hemoglobin and hematocrit: Monitor hemoglobin levels after 1 and 3 months of treatment, then every 3 months thereafter.
Contraindication
None known.
